Form 4: Korro Bio Director Rachel Meyers Granted 6,010 Stock Options

Korro Bio, Inc. director Rachel Meyers was granted 6,010 stock options with an exercise price of $14.87, vesting over one year or by the next annual meeting.

Summary

• Rachel Meyers, a Director of Korro Bio, Inc. (KRRO), was granted 6,010 stock options.
• The transaction date for the option grant was June 11, 2025.
• The exercise price for these stock options is $14.87 per share.
• The options are set to vest in full on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders, contingent on her continued service as a non-employee director.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Rachel Meyers beneficially owns 6,010 derivative securities (stock options).
• An Exhibit 24.1, a Limited Power of Attorney, was filed, authorizing specific individuals to execute SEC filings on behalf of Rachel Meyers.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is a neutral to slightly positive event as it aligns director incentives with shareholder interests. There are no negative financial implications or significant risks disclosed.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the company's stock price increases.
• The options have a long expiration date (June 10, 2035), providing ample time for potential value appreciation.

Future Outlook

The document primarily reports a past transaction (option grant) and its vesting schedule, which extends into the future. It does not provide broader forward-looking statements or financial guidance for the company.

Industry Context

This Form 4 filing is a routine disclosure of director compensation in the form of equity, common practice across publicly traded companies, including those in the biotechnology sector like Korro Bio, Inc. It reflects standard corporate governance practices for aligning director incentives with company performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice in the biotechnology industry, similar to companies like Moderna (MRNA) or BioNTech (BNTX), aiming to attract and retain qualified board members.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity awards, ensuring ongoing commitment to the company's governance.

Corporate Governance

Related Party Transactions

• The grant of stock options to Rachel Meyers, a director, is a transaction between the company and a related party (a member of its board of directors) as part of her compensation.

Stakeholder Impact

• Shareholders: The grant of options to a director is a form of non-cash compensation that aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will vest in full on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to Rachel Meyers' continued service as a non-employee director.

Key Dates

Keywords

Korro Bio, KRRO, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Biotechnology, Pharmaceuticals